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1. INTRODUCTION 
Endothelin-2 (ET-2), originally predicted from its nu- 
clcotide sequence, belongs to the endothelin peptide 
fdrnily [l-3]. Pharmacological studies revealed that ET- 
2 has similar biological activities, including vasocon- 
strictor activity, to ET-l, although its physiological 
roles are not thoroughly clarified [4]. Later, massive 
production of ET-2 by ACHN, a human renal 
adenocarcinoma cell line, was pointed out by isolation, 
amino acid sequence analysis and Northern blot analy- 
sis [5,6]. With respect o the biosynthelic pathway of 
ET-!, we have proposed that ET-1 is produced from a 
39 (porcine) or 38 (human) intermediate form, big ET- I, 
through unusual proteolytic cleavage at Trp”-Val” by 
an ET-converting enzyme (ECE) [!,2]. The biosynthetic 
pathway was confirmed by finding of the related pep- 
tides, ET-l, big ET-!(I-39) and big ET-1(22-39) in the 
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culture supernatant [7]. We have shown that the physio- 
logical importance of the conversion of big ET-l is to 
increase the vasoconstrictor activity by !40-fold on 
cleavage to ET-l [S]. Furthermore, we and others have 
shown that the intracellular conversion from big ET-I 
to ET-l in endothelial cells is markedly inhibited by a 
metalloprotease inhibitor, phosphoramidon, suggesting 
that ET-l-converting enzyme (ECE-1) is a phospho- 
ramidon-sensitive neutral metalloprotcase [9,!0]. 
In contrast to ET-l, the native biosynthetic pathway 
of ET-2 in ET-2-producting cells has not been reported 
yet, although Kosaka et a!. analyzed the biosynthetic 
pathwry using CHO-KI cells transfecled with an cx- 
pression vector containing human prepro-ET-2 cDNA 
[1 11. They suggested that ET-2 is produced from big 
ET-2( l-38) and not from big ET-2( l-37), although the 
latter has been proposed as the intermediate form from 
the nuclcotide sequence of cDNA encoding ET-:! [S]. 
Therefore, we conducted our study to clarify the native 
biosynthetic pathway of ET-2 and the phosphoramidon 
sensitivity of ET-2-converting erzyme (ECE-2) using 
ACHN cells. This is the first demonstration reporting 
the characteristic of ECE-2. 
2. MATERIALS AND METHODS 
I-lllln~? ET-l, ET-2, ET-3 and big ET-2(1-37) were ohlain& from ..“.*a”. -. 
Peptide Institute Inc. (Osaka. Japan). Human big ET-X2-37) was 
oblained from Peninsula Laboratories Inc. (Belmont. CA). Human 
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big ET-2(1-38). big ET-2(22-38) and big ET-2(31-38) were synthe- 
sized by an automated peptidc synthesizer (Applied Biosystems, 
Model 430A). Anti-ET-?(lS-21) untiscrum (As-ETC) was obtained 
from IBL (Tochigi, Japan). Anti-big ET-2(31-38) (As-bET2C) and 
anii-ET-2-(1-21) (As-ETL) antisera were produced with a similar 
method rcportcd previously [12]. Briefly, big ET-2(31-38) or ET-2(1- 
21) was conjugated with keyhole limpet hemocyanin using the glu- 
tnmldchydc oupling procedure. As-bET2C or As-ETL ~35 obtained 
by immunizing New Zcalnnd white rabbits 5 times with the conjugates 
every 2 weeks. ACHN, a human renal ndenocurcinoma cell line, wns 
obtained from American Type Culture Collection. 
ACHN cells were cultured to conflucncc on 90 mm diam. dishes in 
minimum essential medium supplemented with Eurle’s salts, glutamic 
acid, non-cssentinl amino acids (MEM, Gibco. Grand Island, NY), 
10% fetal calf serum, penicillin G (100 U/ml), and streptomycin (100 
,@ml) at 37’C in II CO, incubator (95% air-595 CO?). Then. the 
culture medium was changed to a serum-free medium and furthcl 
incubated for 24 h. The supcrnatonts were collected nnd loaded onto 
a Sep-Pak Cl8 cartridge (Waters, Milford. MA). ET-2-related pep 
tides were eluted with 50% acetonitril (AcCN) in 0.1% trifluoroacctic 
acid (TFA) and separated by a rovers+phase column (Cosmosil SC IS- 
AR, 4.6 x 250 mm, Nacalai tesquc. Kyoto. Japan) with a 37.5 min 
linear gradient of AcCN (12.5-50%) on 0.1% TFA at a flow rate of 
1 mlimin zt 4O’C. Aliquots of fractions were assayed by rodioimmu- 
noassay (RIA) with three nntisern (AsmETC. As-ETL. As-bET2C). 
2.3. Effect uf plrosplrormhh 011 corlwrsion I?_o/JJ big ET-2 to ET-2 
ACHN cells were cultured to confluence in 90 mm diam. dishes as 
described above. Then, the mcclium was changed to u serum-free 
medium with phosphornmidon (IO-“. 10m5, 10e6. IO-‘. and lOmU M) and 
further incubated for 24 h. The supernatants from three dishes 31 each 
concentration were combined and loaded onto a Sep-Pak Cl8 car- 
tridgc and the cluatm were separated on u reverse-phase column (Cos- 
nosil TClbAR, 4.6 x 250 mm) with the same conditions as described 
above. Aliquots of rrdCliOnS were submitted to RIA with the three 
antisera. 
2.4. RI.4 for ET rdured pepricks 
RIAs were performed similarly ns described previously [I?!. ET-1 
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Fig. I. Typical standard curves of big ET-2(1-38) (-e), big ET-2(1- 
37) (-m-), big ET-?(22-38) (G), big ET-2(22-37) (a-), ET-I (-.A-), 
ET-2 (-A-) and ET-3 (--o--) in the RIA with the antiserum As-bET2C. 
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and the monoiodinated pcptides were purified by reverse-phase 
HPLC. Lnbeled ET- I was used as a radioactive lignnd for measuring 
ET-2 using cold ET-2 as standard. EC,s of the antisera to ET-2- 
relntcd peptides were as follows: EC,& of As-bET2C to big ET-2(1- 
35) and big ET-2(22-38) were 295.3 und 198.0 fmol/tube, rcspcctivcly: 
those of As-ETC to ET-I, ET-‘, ET-3 were 310.3, 379.5, 255.7 fmoll 
tube. rcsprctivoly; and lhose of As-ETL lo ET-2, big ET-2(1-38), big 
ET-2(1-37) were 36.8, (X.2, 37.0 fmolltube, respectively. 
3. RESULTS AND DISCUSSION 
3.1. Cross-reactlvr’tks of antisera 
Typical standard curves for RIA with As-bdT2C are 
shown in Fig. 1. As-bET2C recognized big ET-2(1-38) 
and big ET-2(X-38), but not big ET-2(I-37), big ET- 
2(22-37), ET- 1, ET-2 and ET-3 (the cross-reactivity was 
less than 0.1%) The recognition site for As-ETL was 
considered to exist in the loop portion of ET-2, because 
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Fig. 2. Analysis of ir-ET-2-related pepddes in the culture supernnt3nt 
of ACHN cells. The supernatant ~35 separated by revcrsc-phase 
HPLC as described in section 2. Ir-ETQ-related peptidcs were moni- 
tored by As-ETL (a). As-BL’C (b) and As-bEY2C Icj. Arrows indicalo 
the elusion positions of synthetic standurds of big ET 2122-38) (A), big 
ET-2(23-37)(B), big ET-2(l-38) (C), big ET-2(1-37) CD) and ET-2(1- 
21) (E). 
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Fig. 3. Dose dependence of the effects ofphosphoramidon on big ET-2 
conversion. ET-2( I-21) (-•-). big ET-2(1-38) (-•-), big ET-2(22-38) 
(XL), big ET-2(1-37) (-A-) and unknown (-o-1. 
ET-2( l-37) and big ET-2( 1-38). As-ETC recognized the 
C-terminal Trp moiety of ET-l, ET-2 and ET-3, and 
cross-reacted with big ET-2(1-38), -(l-37), -(22-38) and 
-(X-37) less than 0.1% (data not shown). 
Fig. 2 showed the elution pattern of immunorcactive 
(ir)-ET-Z-related peptides after the HPLC. Two major 
ir-peaks (Fraction 58 and 29) and three minor ir-peaks 
(Fraction 52,54 and 44) were detected. Except Fraction 
44, the retention times of Fraction 58, 29, 52 and 54 
corresponded to those of synthetic peptides, ET-2(1- 
21), big ET-&, 7 33-38), big ET-2( 1-38) and big ET-2( i- 
37), respectively, agreeing with the cross-reactivities of 
the three antisera mentioned above, As an example, 
Fraction 58 (ET-2) was recognized with As-ETL and 
As-ETC. No ir-peak could be seen with Fraction 58 
with As-bETX, because As-bET2C cross-reacted with 
ET-2 less than 0.1% (Fig. 1). ACHN cells produced 
almosl equal quantities of big ET-2(22-38) and ET-2(1- 
21) simultaneously into the culture media. Fraction 44 
did not correspond chromatographically to any one of 
the ET-&related peptides mentioned above, and seemed 
to be a fragment of ET-2 or big ET-2 with an N-termi- 
nal loop but not with a free COOH group of C-terminal 
Trp. 
3.3. Effect of yf~o.y7lwatniclon 011 ET-2 prmiuction in 
A CHN cells 
The ir-patterns of ET-Zrelated peptides in the super- 
natznt of ACHN cells incubated with phosphorarnidon 
were observed to be similar to those in Fig. 2. Amounts 
of ET-2( 1-21) and big ET-2(22-38) were decreased, and 
that of big ET-2(1-38) was increased by phosphorami- 
don in a dose-dependent manner (Fig. 3). This metal- 
loprotease inhibitor reversed the ratio of ET-Ubig ET- 
2( l-38) at a concentration of 1 O-G-1O-4 M. The amoum 
of ir-big ET-2(1-37), which has been proposed as an 
intermediate form from the nucleotide sequence of 
cDNA encoding ET-2, did not change significantly in 
the presence of phosphoramidon. These results clearly 
suggest hat the intermediate form, big ET-2, is com- 
posed of 38 amino acid residues with a C-terminal 
arginine, and that phosphoramidon inhibits the activity 
of a putative ECE-2 which produces mature ET-2 from 
big ET-2( I-38). Although the physiological role of ET- 
2 has not been throughly clarified, it should be noted 
that ECE-2 possesses the same enzymatic haracteristic 
as ECE-1 with regard to phosphoramidon sensitivity 
[lo]. Recently, as with the physiologically relevant ECE- 
1 in endothelial cells, a phosphoramidon-sensitive n u- 
tral metalloprotease has been proposed [13]. Further- 
more, it was suggested that ECE-1 can convert also big 
ET-3 to ET-3 [14]. It is of great interest to reveal 
whether or not these enzymes (ECE-1 and ECE-2) have 
the same characteristics with respect o substrate speci- 
ficity to big ETs, and whether or not these enzymes are 
identical. These studies are now in progress. 
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